Perclose for Hematoma

Phase-Based Progress Estimates
UCLA Santa Monica, Los Angeles, CA
Hematoma+3 More
Perclose - Device
All Sexes
What conditions do you have?

Study Summary

This trial is comparing two devices that are used to seal an artery after a transfemoral procedure. It is expected that using both devices will shorten the time it takes to seal the artery, resulting in less time that patients need to lay flat. Perclose is used to treat Hematoma. No patients in this trial will receive a placebo because Perclose has previously been approved by the FDA for a different condition.

Eligible Conditions

  • Hematoma
  • Arterial Occlusion
  • Cardiovascular Diseases
  • Atherogenesis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: At least 15 minutes after abultation occurs for those in the outpatient setting.

At least 15 minutes after abultation occurs for those in the outpatient setting.
Time to Discharge
Hour 24
Percent of patients with hematoma
Time to hemostasis
Hour 24
Time to Ambulation

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Perclose Only
1 of 2
Perclose with Statseal Device
1 of 2
Active Control
Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Perclose · No Placebo Group · N/A

Perclose with Statseal DeviceExperimental Group · 2 Interventions: Perclose, Statseal · Intervention Types: Device, Drug
Perclose Only
ActiveComparator Group · 1 Intervention: Perclose · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at least 15 minutes after abultation occurs for those in the outpatient setting.
Closest Location: UCLA Santa Monica · Los Angeles, CA
Photo of Los Angeles 1Photo of Los Angeles 2Photo of Los Angeles 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Hematoma
0 CompletedClinical Trials

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,382 Previous Clinical Trials
6,521,052 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patient undergoing diagnostic angiography or PCI with femoral access who undergo PercloseTM closure.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.